Background: Accumulating evidence suggests that platelet-derived growth factor-BB (PDGFdisordered angiogenesis of pulmonary arteries, which are histological hallmarks of PAH, we
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Introduction
Pulmonary artery hypertension (PAH) is a progressive pulmonary vascular disease characterized by vasoconstriction, vascular remodeling, and increased vascular resistance; PAH leads to right heart failure and death [1] [2] [3] . To date, there is no cure for the disease, and the mortality rate in PAH patients is fairly high. Therefore, elucidating the molecular and cellular basis underlying the pathogenesis of PAH and exploring new therapeutic strategies are necessary [4] .
It is well known that PAH is caused by aberrant vasculature, which consists of endothelial adhesion and tube formation of ECs have been demonstrated to promote new vessel growth and angiogenesis, which may lead to intimal hyperplasia and vascular abnormalities [5] [6] [7] [8] [9] . Although hyper-proliferative ECs and disordered angiogenesis are crucial for vascular remodeling in PAH [8, 9] , the mechanisms regulating hypoxia-induced angiogenesis have not yet been completely elucidated. Angiogenesis, a physiological process involving the growth of new blood vessels from preexisting vessels, occurs due to a series of events, beginning with the disruption of the endothelial cell basement membrane and extracellular matrix (ECM) by proteolytic enzymes [10] . Degradation of the ECM releases basement membrane-sequestered angiogenic factors, important roles in the survival, proliferation, and migration of tumor cells [14, 15] . However, the role of VEGF in pulmonary vascular angiogenesis and pulmonary artery endothelial cell proliferation, migration and cell cycle progression is not yet clear.
Other peptide growth factors, such as platelet-derived growth factor (PDGF), that elicit their signals via highly selective receptor tyrosine kinases seem to play a prominent role in pulmonary vascular remodeling [15, 16] . Data from atherosclerosis and restenosis models support an important role of PDGF in vivo [17, 18] . In the context of PAH, several studies have reported that the tyrosine kinase inhibitor imatinib is effective for treating PAH induced by pulmonary tumor thrombotic microangiopathy [19] . Indeed, PDGF is a pivotal regulator of neointimal enlargement and stimulates vascular smooth muscle cell migration from the pulmonary vascular remodeling [16] . PDGF-mediated PAH involves multiple mechanisms, . In addition, mechanisms responsible for activating VEGF expression are currently unknown.
involved in the pathogenesis of PAH.
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Materials and Methods

Animal use
bought from the Experimental Animal Center of Harbin Medical University and were approved by the Institutional Animal Care and Use Committee. This study was also approved by the ethics review board of
Animals and lung tissues preparation inspired oxygen (FiO
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the right jugular vein was exposed, the catheter was inserted into the vein, then was advanced into the calculation of the right ventricular hypertrophy index (ratio of right ventricular free wall weight over sum of Echocardiography arterial velocity time integral (PA-VTI), pulmonary arterial pre-ejection time (PA-PET), and pulmonary arterial ejection time (PA-ET) were measured.
Results
hypoxia-induced PH or MCT-induced PH in rats
Hypoxia-and MCT-induced pulmonary hypertension (PH) rat models were used to evaluate the effects of the PDGF-receptor-tyrosine kinase inhibitor imatinib and the multitargeted VEGF-receptor inhibitor sunitinib malate on the development of hypoxia-induced inhibited hypoxia-induced PH or MCT-induced PH development [assessed by pulmonary artery acceleration time(PAAT), pulmonary arterial velocity time integral (PAVTI),right vascular muscularization and right ventricular hypertrophy [48] . These results suggest that of multiple factors, and these factors may have synergistic or mutually antagonistic roles in the development of pulmonary hypertension. Although our study did not explore the role pathway. Therefore, further research is still required to clarify the mechanism of this novel signaling pathway. Studies have shown that the proliferation and migration of PAECs play a key role in excessive pulmonary angiogenesis and endothelial dysfunction [49] . In this paper, we found resulting in dysfunctional pulmonary angiogenesis.
In conclusion, chronic hypoxia promotes PAEC angiogenesis. A novel signaling pathway (see Fig. 8 ). The considerable information outlined in this study may help to understand the pathogenesis of PAH as well as aid in the design of new therapeutic strategies for the treatment of PAH in the future.
